Stay updated on FF-10101-01 Study in Relapsed AML Clinical Trial
Sign up to get notified when there's something new on the FF-10101-01 Study in Relapsed AML Clinical Trial page.

Latest updates to the FF-10101-01 Study in Relapsed AML Clinical Trial page
- Check4 days agoChange DetectedThe completed Phase 1 FF-10101-01 study record is displayed, with details on the trial design, eligibility, locations, and outcome measures.SummaryDifference66%

- Check11 days agoChange DetectedThe site footer revision changed from v3.7.2 to v3.8.0. The page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedAn NIH-wide notice about terminology and website updates appears above the 403 error page. The footer revision label changes from v3.7.1 to v3.7.2.SummaryDifference1%

- Check39 days agoChange DetectedThe footer revision identifier changes from v3.7.0 to v3.7.1; the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check53 days agoChange DetectedThe page now shows a 403 Forbidden error with a minimal header and a Home option, replacing the previously visible study details with an access-block message.SummaryDifference21%

- Check60 days agoChange DetectedThe page shows a revision update from v3.6.6 to v3.7.0, indicating a new release of the page or platform. This update seems to affect the UI/versioning rather than the study details, eligibility criteria, or results.SummaryDifference0.1%

Stay in the know with updates to FF-10101-01 Study in Relapsed AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the FF-10101-01 Study in Relapsed AML Clinical Trial page.